Induced pluripotent stem cells (iPSCs)
Ataxia-Telangiectasia (A-T)
Johns Hopkins UniversityCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Ataxia-Telangiectasia (A-T) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Conjugated Pneumococcal Vaccine Institute of Child Health | Phase 3 | BB |
N-Acetyl-L-Leucine IntraBio Inc | Phase 3 | B |
TAMOXIFEN Dana-Farber Cancer Institute | Phase 2 | CCC |
EXEMESTANE Dana-Farber Cancer Institute | Phase 2 | CCC |
N-ACETYL LEUCINE | D | |
Mbm-01 Matrix Biomed, Inc. | Phase 2 | NR |
Same molecule, other indications
Induced pluripotent stem cells (iPSCs) is also rated in:
global developmental delay with or without impaired intellectual developmentDormant
D
Indicative ·
30 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →